Clinical trial · Observational
A Registry for People With Lung Cancer
Pulmonary Segmentectomy for Lung Cancer: A Real-World International Registry-TSOG 108
NCT06424327CI-TRIAL-00121070recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer Stage I | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patient-Reported Outcomes Measurement Information System | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Participants with Lung Cancer
- description
- Participants undergoing planned pulmonary segmentectomy for primary lung cancer
- interventionNames
- Other: Patient-Reported Outcomes Measurement Information System
Primary outcomes (2)
- measure
- Determine 3-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer.
- timeFrame
- 3 years
- description
- DFS is measured from the date of surgery to the date of recurrence or death
- measure
- Determine 5-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer.
- timeFrame
- 5 years
- description
- DFS is measured from the date of surgery to the date of recurrence or death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years * Patients suitable for segmentectomy, according to the treating surgeon * Clinical Stage I with suspected NSCLC, classified preoperatively based on the AJCC TNM staging manual, 9th edition o Note: Tissue diagnosis of NSCLC is not required before enrollment. A pathologic diagnosis of NSCLC may be confirmed preoperatively with biopsy, intraoperatively with frozen section, or postoperatively on final pathology Exclusion Criteria: * Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years * History of chemotherapy or radiation therapy for a previous lung cancer * Synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery * Carcinoid tumors * History of other malignancies within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix * Actively receiving treatment for other malignancies * Cases of lobectomy in conjunction with segmentectomy from another lobe and ≥2 segmentectomies from different lobes either en bloc or separate will be excluded from the primary analysis. * Multi-segmental resection from the same lobe is not a criterion for exclusion.
References
Publications (0)
Data not yet available
No reference posted for this study.